© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma
Vescio Debates Quadruplet Versus Triplet Therapy in Newly Diagnosed Multiple Myeloma
July 03, 2020
Robert A. Vescio, MD, discussed two treatment options for a 51-year-old male patient with newly diagnosed multiple myeloma.
Isatuximab Triplet Regimen Improves PFS Compared With Doublet in Relapsed Myeloma
June 30, 2020
In an interview with Targeted Oncology, Phillipe Moreau, MD, discussed the findings from the IKEMA trial and what these date mean for the treatment landscape of relapsed multiple myeloma.
SWOG 1211 Shows Longer Efficacy Than Historical Data for Multiple Myeloma
June 26, 2020
Saad Z. Usmani, MD, discusses the phase 2 SWOG 1211 trial investigating bortezomib, lenalidomide, and dexamethasone with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma.
FDA’s ODAC to Review Belantamab Mafodotin BLA for R/R Multiple Myeloma
June 22, 2020
The FDA has announced plans to convene a meeting of the Oncologic Drugs Advisory Committee to review the Biologic License Application for belantamab mafodotin as treated of patients with relapsed or refractory multiple myeloma.
Study Identifies Independent Predictors of Smoldering Multiple Myeloma Progression
June 09, 2020
“We found that the genomic alterations with smoldering multiple myeloma are essentially the same as full-fledged myeloma. This suggests that by the time smoldering multiple myeloma is diagnosed, most of the molecular abnormalities found in myeloma have already occurred.”
JNJ-4528 Remains Under Evaluation for Relapsed/Refractory Multiple Myeloma
June 03, 2020
Jesus Berdeja, MD, discusses the next steps for the chimeric antigen receptor T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 trial in patients with relapsed/refractory multiple myeloma.
Teclistamab Appears Safe, Efficacious in Relapsed/Refractory Multiple Myeloma
May 30, 2020
Another treatment option would be a welcome change for these patients, who tend to have poor prognoses once they run out of treatment options, according to Saad Z. Usmani, MD. After becoming refractory to available therapies, median overall survival is 6-11 months.
High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma
May 30, 2020
“Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma."
Deep and Durable Responses Still Observed With JNJ-4528 in Relapsed/Refractory Myeloma
May 29, 2020
According to the lead study author Jesus G. Berdeja, MD, the overall response rate was 100%, with a stringent complete response rate of 86%. Further, the progression-free survival rate was 86% at 9 months.
Belantamab Mafodotin Shows Signs of Durable Benefit in R/R Multiple Myeloma
May 29, 2020
"In this trial, we show deep and durable responses with single-agent [belantamab mafodotin] were sustained with longer follow-up in this relapsed/refractory multiple myeloma population."